In the case of novel variants, classification was established following the standard protocol as per ACMG/AMP for variant interpretation for genetic hearing loss and the updated recommendations of the ClinGen Hearing Loss Expert Panel, and in some cases (LARS2 and MYO6), their final classification was further established through molecular modeling and in silico strategies. This evidence concerns the gene MYO6 and hearing loss disorder.